 Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced the publication of data in the journal Nature Communications that support the companys proprietary approach to precisely upregulate protein expression using TANGO Targeted Augmentation of Nuclear Gene Output antisense oligonucleotides ASOs. 